OTCPK:MDBI.F

Stock Analysis Report

Executive Summary

Medibio Limited, a medical health technology company, engages in the development of diagnostic systems for mental health illnesses in Australia and the United States.

Snowflake

Fundamentals

Mediocre balance sheet and overvalued.

Risks

  • Medibio has significant price volatility in the past 3 months.
  • Medibio is not covered by any analysts.

Share Price & News

How has Medibio's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-9.1%

MDBI.F

2.5%

US Healthcare Services

-0.6%

US Market


1 Year Return

-76.6%

MDBI.F

10.2%

US Healthcare Services

0.7%

US Market

MDBI.F underperformed the Healthcare Services industry which returned 10.3% over the past year.

MDBI.F underperformed the Market in United States of America which returned 0.6% over the past year.


Share holder returns

MDBI.FIndustryMarket
7 Day-9.1%2.5%-0.6%
30 Day-44.1%-1.9%2.9%
90 Day29.9%-2.9%1.3%
1 Year-76.6%-76.6%10.3%10.2%2.9%0.7%
3 Yearn/a51.7%51.4%44.6%35.2%
5 Yearn/a52.0%51.1%61.9%44.2%

Price Volatility Vs. Market

How volatile is Medibio's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Medibio undervalued based on future cash flows and its price relative to the stock market?

0.35x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Medibio to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Medibio to establish if it is available at substantial discount.


Price Based on Earnings

Medibio is loss making, we can't compare its value to the US Healthcare Services industry average.

Medibio is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Medibio, we can't assess if its growth is good value.


Price Based on Value of Assets

Medibio is good value based on assets compared to the US Healthcare Services industry average.


Next Steps

Future Growth

How is Medibio expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.7%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Medibio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of MDBI.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Medibio's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Medibio performed over the past 5 years?

-27.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Medibio does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Medibio's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Medibio's 1-year growth to the US Healthcare Services industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Medibio has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Medibio has efficiently used its assets last year compared to the US Healthcare Services industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Medibio improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Medibio's financial position?


Financial Position Analysis

Medibio's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

Medibio has no long term commitments.


Debt to Equity History and Analysis

Medibio's level of debt (32%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (71.7% vs 32% today).


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are 0.6x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Medibio has less than a year of cash runway based on current free cash flow.

Medibio has less than a year of cash runway if free cash flow continues to grow at historical rates of 47.9% each year.


Next Steps

Dividend

What is Medibio's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Medibio's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Medibio's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Medibio has not reported any payouts.

Unable to verify if Medibio's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Medibio has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Medibio's salary, the management and board of directors tenure and is there insider trading?

1.3yrs

Average management tenure


CEO

Dave Kaysen (69yo)

0.8yrs

Tenure

0

Mr. David B. Kaysen, also known as Dave, serves as CEO and Managing Director at Medibio Limited since November 2018 and also serves as its Director. He has been the Chairman at Medibio Limited since Februa ...


Management Age and Tenure

1.3yrs

Average Tenure

The average tenure for the Medibio management team is less than 2 years, this suggests a new team.


Board Age and Tenure

0.7yrs

Average Tenure

The average tenure for the Medibio board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyAU$345,24902 Sep 19
FIL Limited
EntityCompany
Shares51,300,000
Max PriceAU$0.0067
BuyAU$168,70029 Aug 19
Marble Bar Asset Management LLP
EntityCompany
Shares25,000,000
Max PriceAU$0.0067
BuyAU$304,91518 Mar 19
FIL Limited
EntityCompany
Shares21,599,156
Max PriceAU$0.014
BuyAU$5,79413 Nov 18
Christopher Indermaur
EntityIndividual
Shares200,000
Max PriceAU$0.029
BuyAU$4,20008 Nov 18
Peter Carlisle
EntityIndividual
Role
Chairman of Advisory Board
Chairman of Growth & Advocacy Advisory Board and Lead Independent Director
Shares120,000
Max PriceAU$0.035
BuyAU$6,81608 Nov 18
Andrew Maxwell
EntityIndividual
Shares216,002
Max PriceAU$0.032

Ownership Breakdown


Management Team

  • Dave Kaysen (69yo)

    Chairman

    • Tenure: 0.8yrs
  • Melanie Jaye Leydin (46yo)

    Joint Company Secretary & Director

    • Tenure: 0.6yrs
    • Compensation: AU$177.84k
  • Michael Player

    Head of Research

    • Tenure: 3.5yrs
  • Josh Purdy

    Public Relations Director

    • Tenure: 0yrs
  • Matt Flax

    Head of Algorithm Development Team

    • Tenure: 3.5yrs
  • Stephanie Ottens

    Investor Relations Director

    • Tenure: 0yrs
  • Adam William Darkins

    Consultant

    • Tenure: 1.7yrs
    • Compensation: AU$29.13k
  • Archie Defillo

    Chief Medical Officer & Member of the Scientific Advisory Board

    • Tenure: 1.4yrs
  • Jennifer Solitario

    Senior Vice President of Corporate Health

    • Tenure: 1yrs
  • Peggy Morgan

    Corporate Controller

    • Tenure: 0.7yrs

Board Members

  • Dave Kaysen (69yo)

    Chairman

    • Tenure: 0.8yrs
  • Claude Solitario

    Non-Executive Director

    • Tenure: 0.8yrs
  • Melanie Jaye Leydin (46yo)

    Joint Company Secretary & Director

    • Tenure: 0.6yrs
    • Compensation: AU$177.84k
  • Peter Carlisle

    Chairman of Growth & Advocacy Advisory Board and Lead Independent Director

    • Tenure: 0.08yrs
    • Compensation: AU$71.71k
  • Patrick Kennedy

    Member of Growth & Advocacy Advisory Board

    • Tenure: 0.08yrs
    • Compensation: AU$71.71k
  • Michael Phelps

    Member of Growth & Advocacy Advisory Board

    • Tenure: 0.08yrs
    • Compensation: AU$71.71k
  • Archie Defillo

    Chief Medical Officer & Member of the Scientific Advisory Board

    • Tenure: 1.4yrs
  • Martin Chapman

    Member of Scientific Advisory Board

    • Tenure: 1.4yrs
  • Joel Ehrenkranz

    Member of Scientific Advisory Board

    • Tenure: 1.4yrs
  • Mark Frye

    Member of Scientific Advisory Board

    • Tenure: 1.4yrs

Company Information

Medibio Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Medibio Limited
  • Ticker: MDBI.F
  • Exchange: OTCPK
  • Founded: 1998
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: AU$11.942m
  • Listing Market Cap: AU$8.085m
  • Shares outstanding: 995.13m
  • Website: https://www.medibio.com.au

Location

  • Medibio Limited
  • 8696 Eagle Creek Circle
  • Savage
  • Minnesota
  • 55378
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MEBASX (Australian Securities Exchange)YesOrdinary SharesAUAUDJan 2001
MEBCHIA (Chi-X Australia)YesOrdinary SharesAUAUDJan 2001
MDBI.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJan 2001
BPNDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJan 2001

Biography

Medibio Limited, a medical health technology company, engages in the development of diagnostic systems for mental health illnesses in Australia and the United States. It is involved in the research, develo ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/22 00:28
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.